Blood Brain Barrier Market (3rd Edition): Industry Trends and Global Forecasts, till 2035

Blood Brain Barrier Market (3rd Edition): Industry Trends and Global Forecasts, till 2035

The Blood Brain Barrier Market is valued at USD 36 million in 2024 growing at a CAGR of 49% during the forecast period 2024-2035.

The focus of blood-brain barrier drugs and technologies is to address the challenges posed by the selective nature of the blood-brain barrier, enabling therapeutic agents to reach the brain directly. Recent years have seen increased research and investment to understand and overcome these challenges, driven by rising incidences of neurological diseases like Alzheimer's and Parkinson's. This trend is expected to drive demand for therapies that bypass the blood-brain barrier, fostering innovation and expanding the market in this area. Innovations include drug delivery systems, nanoparticles, and medical devices aimed at enhancing treatment efficacy for neurological disorders by improving drug transport across the blood-brain barrier.

According to a study by the World Health Organization (WHO), diseases affecting the central nervous system (CNS) such as Alzheimer’s disease, brain cancer, multiple sclerosis, Parkinson’s disease, and stroke have a significant unmet need for effective treatments. Neurological disorders are the second leading cause of death and the foremost cause of disability worldwide. In 2021, it was reported that nearly 3.4 billion people globally suffer from CNS disorders, with over 6 million people living with Alzheimer’s, a figure expected to nearly double by 2050. In the US, nearly one million people are affected by Parkinson’s disease, with approximately 90,000 new diagnoses annually. Extensive research and development efforts have yielded a variety of versatile blood-brain barrier technologies designed to enhance the permeability of the barrier or improve the brain-penetrating capabilities of pharmacological treatments. These advancements have attracted numerous new players to the field, suggesting significant growth potential in the years ahead.

Currently, the blood-brain barrier market is largely driven by technology licensing activities, as drug developers collaborate with platform providers to advance their therapeutic pipelines.



Key Market Segments

Type of Molecule

• Small Molecules
• Biologics

Target Disease Indication

• Multiple Sclerosis
• Amyotrophic Lateral Sclerosis
• Mucopolysaccharidosis Type II (Hunter Syndrome)
• Leptomeningeal Carcinomatosis
• Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A)

Route of Administration

• Oral
• Intravenous

Therapeutic Area

• Neurodegenerative Disorders
• Lysosomal Storage Disorders
• Neuro-Oncology Disorders

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

Research Coverage:

• This chapter begins with an overview of the blood-brain barrier, discussing its importance in light of the increasing prevalence of neurological disorders. It covers various strategies for delivering drugs to the central nervous system (CNS), including both invasive and non-invasive techniques. The chapter also delves into the complexities of penetrating the blood-brain barrier and delivering drugs effectively to the CNS, highlighting the associated challenges.
• The chapter offers a comprehensive introduction to essential concepts concerning the structure of the human brain, its components, and their roles within the central nervous system (CNS). It extensively covers both invasive and non-invasive methods utilized for drug delivery to the CNS. Additionally, it provides a detailed overview of the blood-brain barrier, tracing its historical development and emphasizing its crucial role in facilitating effective drug delivery amid the rising incidence of neurological disorders. The chapter further explores prominent strategies employed to develop drugs and technologies capable of crossing the blood-brain barrier or circumventing it. Finally, it addresses the primary challenges associated with utilizing blood-brain barrier penetration technologies to enhance drug delivery efficiency to the CNS.
• The overview encompasses the current market status of technologies designed to penetrate the blood-brain barrier, providing details on various parameters. These include the development status (commercialized and under development), underlying technology principles (methods for drug delivery, biological approaches, physical techniques, etc.), types of pharmacological molecules compatible with blood-brain barrier penetration (biologics, small molecules, oligonucleotides, etc.), targeted disease indications, patent types, and licensing activities. The overview also profiles technology developers, detailing their establishment year, company size (in terms of workforce), and geographical location.
• Detailed overview of the current market landscape of blood-brain barrier penetrating therapies that are approved or currently being evaluated in clinical trials, featuring a detailed analysis based on relevant parameters, such as stage of development (approved, phase III, phase II, phase I, IND-enabling, pre-clinical and discovery), type of molecule (biologics, small molecules and other molecules), affiliated BBB penetration, route of administration (intranasal, intravenous, oral, subcutaneous and transmucosal) target disease indication and therapeutic area (neurodegenerative disorders, lysosomal storage disorders, neuro oncology disorders, oncological disorders, infectious diseases, pain disorders, autoimmune disorders, CNS disorders, cerebrovascular disorders and others). Additionally, the chapter includes an overview on the landscape of BBB penetrating therapy developers, presenting a detailed analysis based on several relevant parameters, such as year of establishment, company size (based on employee count), location of headquarters and most active players (in terms of the number of therapies).
• Comprehensive company profiles of prominent technology developers (shortlisted based on the following criteria: companies having more than three drugs (being developed using proprietary BBB technologies) in preclinical / clinical phase of development) in this domain, featuring an overview of the company, technology portfolio, product portfolio and recent developments and future outlook.
• A detailed analysis of company competitiveness in the field of blood-brain barrier technologies is conducted based on key parameters. These include developer attributes such as experience duration, company size, and development status. Additionally, the analysis assesses technology strengths, focusing on factors like the types of pharmacological molecules compatible with blood-brain barrier penetration, availability of patent protection, number of collaborations, number of drugs developed, and the highest phase of development achieved.
• This section provides a broad overview of the operational principles underlying prevalent approaches in the development of technologies aimed at penetrating the blood-brain barrier. These approaches include receptor-mediated transcytosis (RMT), which encompasses methods like bispecific antibodies and molecular trojan horse delivery via direct coupling or nanocarriers, strategies to enhance blood-brain barrier permeability, passive diffusion methods, and emerging techniques such as cell-penetrating peptides, macrocycles, and organ-on-a-chip technology.
• An in-depth examination of partnerships within the blood-brain barrier industry is conducted, considering various parameters. These include the year of partnership establishment, partnership type, compatibility of pharmacological molecules, therapeutic area, partner type, and identification of the most active participants based on the number of partnerships formed. Additionally, the analysis covers the regional distribution of partnership activities occurring in this domain from the period prior to 2018 through March 2024.
• This chapter provides a comprehensive exploration of the deal structures found in various types of technology licensing agreements within this field. It includes specifics on the rights pertaining to product ownership, associated royalties, upfront payments, and other contractual terms and conditions among industry stakeholders. The discussion is supported by detailed analysis based on key parameters such as the year of agreement, type of licensing agreement, the most active participants (in terms of the number of licensing agreements), the most popular technologies involved (in terms of the number of licensing agreements), and geographic considerations.
• This analysis focuses on the funding and investments directed towards companies involved in the development of technologies and drugs for blood-brain barrier penetration. It encompasses various sources such as venture capital financing, funds raised through IPOs and subsequent offerings, grants, and debt financing. The detailed examination covers funding events occurring between 2020 and March 2024, emphasizing the increasing interest shown by the venture capital community and other strategic investors in this market.
• This chapter provides a comprehensive analysis of patents filed or granted in the field of the blood-brain barrier since 2018. It examines several parameters including the year of patent publication, geographical distribution, CPC symbols, prominent players based on the number of patents filed or granted, and the type of organizations involved. Additionally, the chapter includes detailed patent benchmarking and valuation analysis, spotlighting leading patents based on the number of citations they have received.
• A strategic analysis showcasing the predominant drug development strategies adopted by a majority of drug developers with clinical candidates in this field. The analysis aims to assist stakeholder companies in enhancing their current drug development approaches to expedite the advancement of their lead drug candidates.
• A comprehensive 3D bubble chart illustrating the market potential of prevalent CNS disorders, prioritized by the number of blood-brain barrier (BBB) penetrant drugs in development. The chart considers metrics such as approved drugs, pipeline drugs, and the target patient population. It also features an in-depth discussion on epidemiological insights, causes, symptoms, ongoing development of BBB penetrant drugs for each specific disease, existing treatment options, and details of drugs already available on the market for each respective indication.
• A compilation of over 240 drug developers focusing on Alzheimer’s disease and Parkinson’s disease, identified as potential partners for providers of blood-brain barrier penetration technologies. These developers have been selected based on criteria including their organizational strength (such as company size and years of experience in the field), the robustness and maturity of their pipelines (in terms of the number of drugs and their developmental stages), targeted indications, types of molecules used, routes of administration, and mechanisms of action.
• Detailed analysis of the factors that can affect the growth of blood-brain barrier market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
• Comprehensive market forecast analysis to estimate the existing market size and future opportunity for global blood-brain barrier penetrating therapies market over the next decade. Based on multiple parameters, such as likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2024-2035. The report also features the likely distribution of the current and forecasted opportunity within the global blood-brain barrier penetrating therapies market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
• Comprehensive projections of the current and future blood-brain barrier penetrating therapies market across different types of molecules, such as small molecules and biologics.
• Comprehensive projections of the current and future blood-brain barrier penetrating therapies market across various routes of administration, such as oral and intravenous.
• Detailed projections of the current and future blood-brain barrier penetrating therapies market across different target disease indications, such as multiple sclerosis, mucopolysaccharidosis type II (hunter syndrome), amyotrophic lateral sclerosis, leptomeningeal carcinomatosis and mucopolysaccharidosis type III A (sanfilippo syndrome A).
• Detailed projections of the current and future blood-brain barrier penetrating therapies market across various therapeutic areas, such as neurodegenerative disorders, lysosomal storage disorders and neuro-oncology disorders.
• Detailed projections of the current and future blood-brain barrier penetrating therapies market across various key geographical regions, such as North America, Europe and Asia-Pacific and Rest of the World.
• Details pertaining to the sales forecast for approved / phase III drugs in the BBB penetrating therapies market.

Key Benefits of Buying this Report

• The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
• Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
• The report provides stakeholders with a pulse on the Blood Brain Barrier Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

• ICBI
• Denali Therapeutics
• JCR Pharmaceuticals
• Cyclenium Pharma
• Lauren Sciences
• biOasis Technologies
• Ossianix
• Angiochem
• Genervon Biopharmaceuticals
• NEUWAY Pharma
• Tranquis Therapeutics
• CERES BRAIN Therapeutics
• Nanomerics
• Reglagene